Interface Biosciences
Interface Bio is a drug discovery company focused on developing next-generation immunotherapies for complex diseases such as autoimmune disorders and cancer. They leverage a proprietary platform that combines precision culturomics, targeted metabolomics, molecular engineering, and AI to mine natural product libraries derived from commensal microbes. These natural products are optimized to create multi-mechanism therapeutics with unprecedented stability, potency, and safety. The company's approach involves an AI-guided search for novel sactipeptides, followed by screening, optimization through AI and rational engineering, and validation in various modeling systems to ensure translation to the clinic. They aim to revolutionize the chemical space by identifying and developing therapeutics from microbial-derived natural products.
Interface Biosciences
Interface Bio is a drug discovery company focused on developing next-generation immunotherapies for complex diseases such as autoimmune disorders and cancer. They leverage a proprietary platform that combines precision culturomics, targeted metabolomics, molecular engineering, and AI to mine natural product libraries derived from commensal microbes. These natural products are optimized to create multi-mechanism therapeutics with unprecedented stability, potency, and safety. The company's approach involves an AI-guided search for novel sactipeptides, followed by screening, optimization through AI and rational engineering, and validation in various modeling systems to ensure translation to the clinic. They aim to revolutionize the chemical space by identifying and developing therapeutics from microbial-derived natural products.
TL;DR
Headquarters & focus: Palo Alto biotech developing AI-guided, microbiome-derived natural-product immunotherapies
Founders: Hannah C. Wastyk, Ph.D. (CEO) and Will Van Treuren, Ph.D. (CSO)
Founded: 2020
Reported seed raise: $3.0M (Dec 2023)
Employee size (reported): ~5
Company Overview
Problem Domain
Complex inflammatory diseases and cancer where multi-mechanism immunotherapies could improve safety and efficacy.
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
$3.0M
Reported December 2023 seed round with participation from multiple investors
Investor Signal
“LongeVC, One Planet Group, Payam Zamani, Pear VC, Ulu Ventures”